Examination of anaplastic thyroid carcinoma cases at our hospital

Abstract

We conducted a clinical review of 24 patients who were diagnosed with anaplastic thyroid carcinoma by histology or cytology and treated at our hospital from September 1, 2016 to December 31, 2023. The 1-year survival rate was 41%. The median survival times of the surgical group and non-surgical group were 12.8 months and 4.7 months, respectively which amounted to a statistically significant difference. When examining only the surgery group, survival times were significantly prolonged in the low NLR and normal Hb/CRP groups. Even in cases of anaplastic thyroid carcinoma, we believe that performing surgery with the aim of achieving a radical cure or local control (based on the patient's background and inflammatory markers) may contribute to the prognosis.